Astellas Bows Out Of Try For CV Therapeutics
This article was originally published in PharmAsia News
Astellas Pharma is canceling plans for a hostile takeover of U.S.-based CV Therapeutics. The decision followed an agreement by CV's board to accept the bid of Gilead Sciences. In addition to withdrawing from the acquisition bid, Astellas also said it would drop its court case that sought to challenge CV's efforts to block the Astellas bid. Astellas ended up bidding $4 per share less than Gilead for control of CV. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.